BRPI0710442A2 - agentes de ligação de proteìna-4 secretada relacionada com frizzled(sfrp-4) - Google Patents

agentes de ligação de proteìna-4 secretada relacionada com frizzled(sfrp-4) Download PDF

Info

Publication number
BRPI0710442A2
BRPI0710442A2 BRPI0710442-1A BRPI0710442A BRPI0710442A2 BR PI0710442 A2 BRPI0710442 A2 BR PI0710442A2 BR PI0710442 A BRPI0710442 A BR PI0710442A BR PI0710442 A2 BRPI0710442 A2 BR PI0710442A2
Authority
BR
Brazil
Prior art keywords
sfrp
polypeptide
antibody
disease
cancer
Prior art date
Application number
BRPI0710442-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Annette Zaar
Rainer Hillenbrand
Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0710442A2 publication Critical patent/BRPI0710442A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
BRPI0710442-1A 2006-02-09 2007-02-08 agentes de ligação de proteìna-4 secretada relacionada com frizzled(sfrp-4) BRPI0710442A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77165106P 2006-02-09 2006-02-09
US60/771651 2006-02-09
PCT/EP2007/051229 WO2007090872A2 (fr) 2006-02-09 2007-02-08 Agents de liaison de la proteine-4 apparentee a frizzled (sfrp-4)

Publications (1)

Publication Number Publication Date
BRPI0710442A2 true BRPI0710442A2 (pt) 2011-08-16

Family

ID=38335655

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710442-1A BRPI0710442A2 (pt) 2006-02-09 2007-02-08 agentes de ligação de proteìna-4 secretada relacionada com frizzled(sfrp-4)

Country Status (9)

Country Link
EP (1) EP1991582A2 (fr)
JP (1) JP2009526020A (fr)
KR (1) KR20080113196A (fr)
CN (1) CN101370826A (fr)
AU (1) AU2007213655A1 (fr)
BR (1) BRPI0710442A2 (fr)
CA (1) CA2637775A1 (fr)
RU (1) RU2008136080A (fr)
WO (1) WO2007090872A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (fr) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Procédé pour le traitement des amyloses
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
CN102965448A (zh) * 2012-12-12 2013-03-13 芮屈生物技术（上海）有限公司 糖尿病病理演变前期SFRP4基因的mRNA水平原位杂交检测试剂盒及检测方法和应用
WO2015172201A1 (fr) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarqueur du cancer gastrique
CN117337394A (zh) 2021-05-17 2024-01-02 豪夫迈·罗氏有限公司 sFRP4作为血液生物标志物用于子宫腺肌病的非侵入性诊断

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075280A2 (fr) * 1999-06-08 2000-12-14 Smithkline Beecham Corporation Membre de la famille frzb
EP1222933A1 (fr) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt
WO2002092128A1 (fr) * 2001-05-11 2002-11-21 Genzyme Corporation Compositions et procedes permettant de reguler le phosphate de serum
EP1808694A1 (fr) * 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Procédé de diagnostic d'une maladie polykystique des reins

Also Published As

Publication number Publication date
CA2637775A1 (fr) 2007-08-16
WO2007090872A3 (fr) 2007-11-29
KR20080113196A (ko) 2008-12-29
AU2007213655A1 (en) 2007-08-16
EP1991582A2 (fr) 2008-11-19
WO2007090872A2 (fr) 2007-08-16
CN101370826A (zh) 2009-02-18
JP2009526020A (ja) 2009-07-16
RU2008136080A (ru) 2010-03-20

Similar Documents

Publication Publication Date Title
BRPI0710442A2 (pt) agentes de ligação de proteìna-4 secretada relacionada com frizzled(sfrp-4)
US7741056B2 (en) Use of A33 antigens and JAM-IT
US8367356B2 (en) Gelsolin binding agent compositions and uses of same
TW201829461A (zh) 中和抗tl1a之單株抗體
BRPI0808940B1 (pt) Anticorpo humano-murino quimérico ou xegogeneico, humanizado, humano ou seu fragmento de ligação, vetor de expressão, microrganismo transgênico, método para preparar um anticorpo ou um fragmento de ligação, composição, composição de diagnóstico, uso do anticorpo ou fragmento de ligação, kit para o diagnóstico de um tumor e uso da molécula de antígeno ligante ao tumor
US20210032350A1 (en) Antibodies to galectin-3 and methods of use thereof
KR102611444B1 (ko) 플렉틴-1 결합 항체 및 그의 용도
WO2017028279A1 (fr) Agents de liaison au récepteur de trail et leurs utilisations
WO2006026172A2 (fr) Utilisation de cd26 soluble en tant qu'inhibiteur de l'angiogenese et de l'inflammation
MX2008010145A (en) Antibodies against secreted fri zzled related protein-4 (sfrp-4 )
WO2016074245A1 (fr) Agents de fixation du récepteur trail et leurs utilisations
ZA200502502B (en) Use of A33 antigens and jam-it

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A E 5A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.